Palifermin: Role in the Prevention of Chemotherapy- and Radiation-Induced Mucositis

@article{McDonnell2007PaliferminRI,
  title={Palifermin: Role in the Prevention of Chemotherapy- and Radiation-Induced Mucositis},
  author={Anne M. McDonnell and Kristi L. Lenz},
  journal={Annals of Pharmacotherapy},
  year={2007},
  volume={41},
  pages={86 - 94}
}
Objective: To assess the efficacy, toxicity, and potential cost benefit of palifermin in the prevention of chemotherapy- and radiation-induced mucositis. Data Sources: MEDLINE and PubMed database searches were conducted (1966–May 2006) using the following search terms: palifermin, human keratinocyte growth factor, fibroblast growth factor, mucositis, and stomatitis. Study Selection And Data Extraction: All published clinical trials and abstracts examining the use of palifermin, as well as… 

Tables from this paper

Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.

Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning

A single-centre, single-arm, retrospective analysis of consecutive patients receiving total body irradiation and chemotherapy conditioning for auHSCT or aHSCT from 1 January 2008 to 31 December 2019 found shorter courses of palifermin may provide the clinical benefit of mucosal thickening at a less prohibitive cost for routine use.

Non-invasive detection of a palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats

The in vivo SBT and in vitro sucrase assay were used to evaluate small intestinal function and damage and the ability of palifermin to modify the functional capacity of the small intestine in rats with intestinal mucositis was monitored.

Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin

Results suggest that dose adjustments for heparin and palifermin are not warranted when administered concurrently, and changes in the pharmacokinetics ofPalifermin during coadministration of heparIn did not affect the pharmacodynamic effect of palifermine, or the anticoagulant activity of heParin, and did not lead to increased safety findings.

Alterações bucais e cuidados orais no paciente transplantado de medula óssea

Key questions in national and international literature with reference to oral inflammatory conditions of BMT patients, both those with predisposition to complications during the transplant and those that emerge during and after myelosuppression therapy are discussed.

Interventions for preventing oral mucositis for patients with cancer receiving treatment.

Ten interventions were found to have some benefit with regard to preventing or reducing the severity of mucositis associated with cancer treatment, and implications for practice include consideration that benefits may be specific for certain cancer types and treatment.

References

SHOWING 1-10 OF 27 REFERENCES

Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.

Palifermin Reduces Estimated Downstream Costs of Autologous Stem Cell Transplant (SCT): Analysis of Phase 3 Trial Results.

The clinical efficacy of palifermin should lead to significant hospital cost savings for pts with hematologic malignancies undergoing auto-SCT following HDC and TBI, and the magnitude of savings will depend on the cost of the drug.

The effect of oral mucositis on morbidity and mortality in bone marrow transplant.

Reduction in the severity and duration of oral mucositis and its sequelae in patients undergoing bone marrow transplantation can have a substantial impact on morbidity and mortality and cost of care.

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

  • D. BrizelT. Wasserman R. Sauer
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
With and without amifostine, 2-year local-regional control, disease-free survival, and overall survival were 58% versus 63, 53% versus 57%, and 71% versus 66%, respectively, while Antitumor treatment efficacy was preserved.

Keratinocyte growth factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host-disease (AGVHD) in patients at high risk of AGVHD

Preliminary data suggest that the administration of palifermin through the time of engraftment possibly has a survival benefit in patients at high risk for acute GVHD, perhaps mediated through an interaction with methotrexate.

Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.

  • N. MeropolR. Somer L. Rosen
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
KGF is generally well tolerated when administered IV at doses up to 40 microg/kg/d for 3 days before a 5-day course of FU plus leucovorin and a clinically meaningful biologic effect was suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treating with placebo.

Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis

An expert panel was assembled to evaluate the literature and to create evidence‐based guidelines for preventing, evaluating, and treating mucositis.

Phase I/II Randomized Trial Evaluating the Safety and Clinical Effects of Repifermin Administered to Reduce Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Repifermin given before and after auto-HSCT seems to be active in reducing mucositis, but a larger trial will be necessary to determine the efficacy of repifermin with this dose schedule.

Oral mucositis--the search for a solution.

The oral cavity is a complex environment composed of tissues with different origins, structures, and functions that is disrupted in oral mucositis, a serious complication of high-dose chemoradiotherapy that affects up to 75% of patients who undergo hematopoietic stem-cell transplantation and 77 percent of patients with head and neck cancer who receive such treatment.

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

It is concluded that amifostine can be safely administered prior to high-dose melphalan and significantly reduces the frequency and severity of therapy-induced oral mucositis.